Results 11 to 20 of about 612,123 (266)

Molecular targeted therapy for anticancer treatment. [PDF]

open access: yesExp Mol Med, 2022
AbstractSince the initial clinical approval in the late 1990s and remarkable anticancer effects for certain types of cancer, molecular targeted therapy utilizing small molecule agents or therapeutic monoclonal antibodies acting as signal transduction inhibitors has served as a fundamental backbone in precision medicine for cancer treatment.
Min HY, Lee HY.
europepmc   +3 more sources

Molecular Targets for AIDS Therapy [PDF]

open access: yesScience, 1990
The development of antiretroviral therapy against acquired immunodeficiency syndrome (AIDS) has been an intense research effort since the discovery of the causative agent, human immunodeficiency virus (HIV). A large array of drugs and biologic substances can inhibit HIV replication in vitro.
Mitsuya, H., Yarchoan, R., Broder, S.
openaire   +3 more sources

Molecular targeted therapy of glioblastoma [PDF]

open access: yesCancer Treatment Reviews, 2019
Glioblastomas are intrinsic brain tumors thought to originate from neuroglial stem or progenitor cells. More than 90% of glioblastomas are isocitrate dehydrogenase (IDH)-wildtype tumors. Incidence increases with age, males are more often affected. Beyond rare instances of genetic predisposition and irradiation exposure, there are no known glioblastoma ...
Le Rhun, Emilie   +7 more
openaire   +4 more sources

Targeted Molecular Therapies for SBMA [PDF]

open access: yesJournal of Molecular Neuroscience, 2015
Spinal and bulbar muscular atrophy (SBMA) is a late-onset neuromuscular disease caused by a polyglutamine expansion in the androgen receptor gene which results in progressive spinal and bulbar motor neuron degeneration, and muscle atrophy. Although the causative genetic defect is known, until recently, the molecular pathogenesis of the disease was ...
Rinaldi, C, Malik, B, Greensmith, L
openaire   +3 more sources

Molecular imaging and targeted therapies [PDF]

open access: yesBiochemical Pharmacology, 2010
Targeted therapeutic and imaging agents are becoming more prevalent, and are used to treat increasingly smaller segments of the patient population. This has lead to dramatic increases in the costs for clinical trials. Biomarkers have great potential to reduce the numbers of patients needed to test novel targeted agents by predicting or identifying non ...
David L, Morse, Robert J, Gillies
openaire   +2 more sources

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

open access: yesMolecular Cancer, 2021
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all CRC cases; its mutations result in constitutive ...
Gongmin Zhu   +4 more
doaj   +1 more source

Targeted Molecular Therapy of GBM

open access: yesBrain Pathology, 2003
Major advances in molecular biology, cellular biology and genomics have substantially improved our understanding of cancer. Now, these advances are being translated into therapy. Targeted therapy directed at specific molecular alterations is already creating a shift in the treatment of cancer patients.
Paul S, Mischel, Timothy F, Cloughesy
openaire   +3 more sources

A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance

open access: yesFrontiers in Cell and Developmental Biology, 2020
In recent years, as our understanding of tumor immunology is continuously improved, immunotherapy has come to the center stage of cancer therapy and is deemed as the most promising approach for cancer control.
Qian Huang   +4 more
doaj   +1 more source

Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells

open access: yesFrontiers in Oncology, 2022
While PARP inhibitor (PARPi) therapies have shown promising results in the treatment of high-grade serous ovarian cancer (HGSOC) harboring homologous recombination deficiencies, primary resistance to PARPi frequently occurs and even initial responders ...
Yaxun Jia   +6 more
doaj   +1 more source

Menin–MLL1 Interaction Small Molecule Inhibitors: A Potential Therapeutic Strategy for Leukemia and Cancers

open access: yesMolecules, 2023
Encoded by the MEN1 gene, menin protein is a fusion protein that is essential for the oncogenic transformation of mixed-lineage leukemia (MLL) and leads to acute leukemia (AL). Therefore, accumulating evidence has demonstrated that inhibition of the high-
Qing Shi   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy